England Expanding Pharmacy First Program With £340M Investment

England is expanding its Pharmacy First scheme this autumn, backed by £340 million in new government investment.

Starting in 2024, the program already lets pharmacists prescribe medication for seven specific conditions: sinusitis, sore throat, earache, infected insect bites, impetigo, shingles, and uncomplicated urinary tract infections in women. No GP appointment needed. Walk in, get treated.

Five more conditions are being added to that list. The government has not yet named what those five are.

The Numbers

According to the Department of Health and Social Care, more than 3.3 million consultations were conducted under Pharmacy First between March 2025 and February 2026.

Over 10,000 pharmacies — more than 95% of all pharmacies in England — signed up from day one, according to NHS England. Four in five people in England can reach a community pharmacy within a 20-minute walk.

The original scheme launched by Rishi Sunak's government in early 2024 was backed by £645 million over two years and projected to free up 15 million GP appointments over that period, according to The Guardian's reporting at the time.

Health Minister's Position

Health Minister Stephen Kinnock called the expansion a way of "making the most of our highly skilled pharmacists, while boosting access to services and giving patients more care right on their doorstep."

He specifically flagged independent prescribing as key, claiming it will "ease pressures on GPs, cutting unnecessary red tape."

The pressure problem is documented: according to The Guardian, in a five-month stretch prior to the original 2024 launch, 24 million consultations took place more than two weeks after patients first requested them — roughly 5 million delayed appointments every month.

Industry Concerns

The National Pharmacy Association — the NPA — says the deal "points in the right direction" but isn't enough.

Their core complaint: rising business rates, employer costs, and medicine prices are hammering pharmacies financially. The government is asking pharmacists to do more clinical work while the business model underneath them is being squeezed.

Expanding services is difficult to sustain if the pharmacies delivering those services are struggling to remain open.

Coverage Gaps

The BBC framed this almost entirely as a feel-good NHS reform story. They gave minimal weight to the NPA's financial warnings, which represent a significant problem for the program's long-term viability.

The Guardian's most detailed reporting dates from over three years ago — their original 2023 scoop on the proposal. Thorrun Govind, then-chair of the Royal Pharmaceutical Society in England, called it a "real game-changer." But even that original coverage noted that experts warned about patients being "bumped from pillar to post" if pharmacies couldn't uniformly deliver the services.

One obvious question remains unaddressed: what are the five new conditions being added? The government announced a major expansion without specifying the actual clinical scope. The original seven conditions were defined precisely, with specific age ranges laid out by NHS England. Shingles for adults 18 and over. Earache for ages 1 to 17. UTIs for women 16 to 64. This specificity exists because these are clinical decisions with real stakes. Vague announcements about mystery conditions raise questions about what's actually being approved.

Reality Check

GP appointment waits in England are a genuine crisis. Pharmacists are trained professionals who are systematically underused. Using them for straightforward, protocol-driven conditions frees up doctors for complex diagnoses.

£340 million sounds substantial. Split across 10,000+ pharmacies over multiple years, though, it's a fraction of what's needed if you're also not fixing the underlying financial pressures those businesses face. Community pharmacy in England has been in financial distress for years.

For patients, this expansion means potentially shorter waits and easier access for common ailments — if local pharmacies remain open to deliver it.